WEST PHARMACEUTICAL SERVICES (WST)
US9553061055 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to WST. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 350.33. This target is 9.18% above the current price.
WST was analyzed by 15 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about WST.
In the previous month the buy percentage consensus was at a similar level.
WST was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-16 | UBS | Maintains | Neutral -> Neutral |
| 2024-02-13 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-07 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-27 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-08-30 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-08-21 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-07-28 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-07-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-06-16 | B of A Securities | Upgrade | Neutral -> Buy |
| 2023-04-11 | Stephens & Co. | Upgrade | Equal-Weight -> Overweight |
| 2023-02-17 | Keybanc | Maintains | Overweight |
| 2022-12-14 | Deutsche Bank | Initiate | Hold |
| 2022-12-02 | Keybanc | Maintains | Overweight |
| 2022-11-30 | UBS | Initiate | Neutral |
| 2022-10-28 | Keybanc | Maintains | Overweight |
| 2022-10-28 | B of A Securities | Downgrade | Buy -> Neutral |
| 2022-04-29 | Keybanc | Maintains | Overweight |
| 2021-07-30 | Keybanc | Maintains | Overweight |